Search results
5 paź 2022 · Juvenile idiopathic arthritis, formerly known as juvenile rheumatoid arthritis, is the most common type of arthritis in children under the age of 16. Juvenile idiopathic arthritis can cause persistent joint pain, swelling and stiffness.
To provide recommendations for the management of juvenile idiopathic arthritis (JIA) with a focus on nonpharmacologic therapies, medication monitoring, immunizations, and imaging, irrespective of JIA phenotype.
5 paź 2022 · Treatment for juvenile idiopathic arthritis focuses on helping your child maintain a normal level of physical and social activity. To accomplish this, doctors may use a combination of strategies to relieve pain and swelling, maintain full movement and strength, and prevent complications.
Onel KB, Shenoi S. 2021 American College of Rheumatology guideline for the treatment of juvenile idiopathic arthritis (JIA): therapeutic approaches for oligoarthritis, temporomandibular joint arthritis (TMJ), and systemic JIA, medication monitoring, immunizations and non-pharmacologic therapies.
To provide updated guidelines for pharmacologic management of juvenile idiopathic arthritis (JIA), focusing on treatment of oligoarthritis, temporomandibular joint (TMJ) arthritis, and systemic JIA with and without mac-rophage activation syndrome.
This clinical practice guideline complements the 2019 ACR JIA and uveitis guidelines, on polyarthritis, sacroiliitis, enthesitis and uveitis, and a concurrent 2021 guideline on oligoarthritis, temporomandibular arthritis and systemic JIA. It serves as a tool to support clinicians, patients and caregivers in decision-making.
To develop treatment recommendations for children with juvenile idiopathic arthritis manifesting as non- systemic polyarthritis, sacroiliitis, or enthesitis. Methods. The Patient/Population, Intervention, Comparison, and Outcomes (PICO) questions were developed and refined by members of the guideline development teams.
